Acimtamig
Based on 1 Customer Validation
Acimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.9%
- CAS 番号: 2738880-26-5
- 分子量:103.936 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
TNFRSF8 & FCGR3A
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD30/TNFRSF8 Protein, Human (HEK293, His, HY-P70023) can bind Acimtamig. The EC50 for this effect is 668.7 ng/mL. -
Immobilized Fc gamma RIIIA/CD16a Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78099) can bind Acimtamig. The EC50 for this effect is 714.0 ng/mL.
Product Details
Product Properties
-
性状
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
純度
99.9%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
輸送条件
Shipping with dry ice.
純度とドキュメンテーション
参考文献
ホットトピック
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics TCE (T cell engager) Potential in Solid Tumors
T-cell engagers (TCEs) are engineered immunotherapeutic molecules designed to redirect endogenous T cells toward tumor cells through simultaneous binding of a T-cell receptor component, most commonly CD3, and a tumor-associated antigen (TAA) expressed on malignant cells.
2026-06-18
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)